Rafet Basar

12PUBLICATIONS
144CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Aug 21, 2026
Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.

|Apr 22, 2026
CAR-NK cell therapy for hematological malignancies.

|Feb 11, 2026
Agent-based modeling of cellular dynamics in adoptive cell therapy.

Yujia Wang, Stefano Casarin, May Daher

|Oct 27, 2025
CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models.

Paul Lin, Sunil Acharya, Francia Reyes-Silva

|Jun 04, 2025
CREM is a regulatory checkpoint of CAR and IL-15 signalling in NK cells.

Hind Rafei, Rafet Basar, Sunil Acharya

|Apr 04, 2025
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial.

Yago Nieto, Pinaki Banerjee, Indreshpal Kaur

Pageof 2

Frequent Collaborators

10 joint publications

Katayoun Rezvani

9 joint publications

May Daher

6 joint publications

Hind Rafei

6 joint publications

Vakul Mohanty